Alejandra R. Álvarez

Alejandra R. Álvarez


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2024 in Cell Reports
Verified
Journal Article
Open access
ACAmérica Chandía-Cristi
América Chandía-Cristi
DGDaniela A. Gutiérrez
Daniela A. Gutiérrez
ADAndrés E. Dulcey
Andrés E. Dulcey
MLMarcelo Lara
Marcelo Lara
LVLina Vargas
Lina Vargas
AÁAlejandra R. Álvarez
Alejandra R. Álvarez
The molecular mechanisms underlying seizure generation remain elusive, yet they are crucial for developing effective treatments for epilepsy. The current study shows that inhibiting c-Abl tyrosine kinase prevents apoptosis, reduces dendritic spine loss, and maintains N-methyl-d-aspartate (NMDA) receptor subunit 2B (NR2B) phosphorylated in in vitro models of excitotoxicity. Pilocarpine-induced status epilepticus (SE) in mice promotes c-Abl phosphorylation, and disrupting c-Abl activity leads to fewer seizures, increases latency toward SE, and improved animal survival. Currently, clinically used c-Abl inhibitors are non-selective and have poor brain penetration. The allosteric c-Abl inhibitor, neurotinib, used here has favorable potency, selectivity, pharmacokinetics, and vastly improved brain penetration. Neurotinib-administered mice have fewer seizures and improved survival following pilocarpine-SE induction. Our findings reveal c-Abl kinase activation as a key factor in ictogenesis and highlight the impact of its inhibition in preventing the insurgence of epileptic-like seizures in rodents and humans.

19 May 2026 in BMC Biology
Verified
Journal Article
Open access
PDF file
NSNicolás Stuardo
Nicolás Stuardo
ÁCÁlvaro Cáceres-Quezada
Álvaro Cáceres-Quezada
DGDiego Guzmán
Diego Guzmán
CLCristian M Lamaizon
Cristian M Lamaizon
NRNancy Leal R.
Nancy Leal R.
AÁAlejandra R. Álvarez
Alejandra R. Álvarez
Axon initial segment (AIS) dysfunction disrupts neuronal compartmentalization, which leads to pathological processes like Tau missorting in Alzheimer’

20 May 2025 in Antioxidants
Verified
Journal Article
Open access
PDF file
Miguel GuerraMiguel Guerra
Miguel Guerra
JCJuan Castro
Juan Castro
AMAntonio Moreno
Antonio Moreno
EBElisa Balboa
Elisa Balboa
JMJuan J. Marugan
Juan J. Marugan
Silvana ZanlungoSilvana Zanlungo
Silvana Zanlungo
Lysosomal storage diseases (LSDs) are characterized by the accumulation of undegraded substrates within lysosomes, often associated with oxidative stress and impaired lysosomal function. In this study, we investigate the role of the c-Abl/TFEB pathway in different LSDs: Gaucher, Niemann-Pick type A (NPA), and Niemann-Pick type C (NPC). Our findings identify c-Abl activation (p-c-Abl) as a common pathogenic mechanism in these disorders. We demonstrate that c-Abl phosphorylates TFEB at Tyr173, leading to its cytoplasmic retention. Using pharmacological models of Gaucher, NPA and NPC in SH-SY5Y neuronal cells and HeLa cells, we assess the effects of the c-Abl inhibitors Imatinib and Neurotinib, as well as the antioxidant α-Tocopherol (α-TOH), on TFEB nuclear translocation and p-c-Abl protein levels. Additionally, we explore the effects of c-Abl inhibitors in cholesterol accumulation in LSDs neuronal models. Our results show that treatment with c-Abl inhibitors or α-TOH promotes TFEB nuclear translocation, enhances lysosomal clearance, and reduces cholesterol accumulation in all three LSD models. These findings highlight the c-Abl/TFEB pathway as a potential therapeutic target for LSDs and potentially other neurodegenerative disorders associated with lysosomal dysfunction.

23 March 2025 in Neurobiology of Disease
Verified
Journal Article
Closed access
AKAndres Klein
Andres Klein
CMCarola Maldonado
Carola Maldonado
LVLina M. Vargas
Lina M. Vargas
MGMarcela Gonzalez
Marcela Gonzalez
FRFermín Robledo
Fermín Robledo
Silvana ZanlungoSilvana Zanlungo
Silvana Zanlungo

9 April 2026 in Antioxidants
Verified
Journal Article
Open access
PDF file
CLCristian M Lamaizon
Cristian M Lamaizon
RTRenatta Tironi-Hernández
Renatta Tironi-Hernández
NANohela B. Arévalo
Nohela B. Arévalo
SASebastián D. Ahumada
Sebastián D. Ahumada
DGDaniela Gutiérrez G
Daniela Gutiérrez G
AÁAlejandra R. Álvarez
Alejandra R. Álvarez
Gaucher disease (GD) is characterized by the accumulation of glucosylceramide within lysosomes due to mutations in the GBA1 gene, which encodes the enzyme glucocerebrosidase. Current treatments are ineffective for patients suffering from severe neuronopathic forms of the disease. In this context, new therapeutic approaches for neuronopathic GD forms are needed. Lysosomal and mitochondrial dysfunction associated with increased oxidative stress and disturbances in the autophagic process have been described in GD. Here, we address c-Abl-RIPK3 signaling and its contribution to the accumulation of dysfunctional mitochondria in GD. Fibroblasts from patients with GBA1 mutations and neurons treated with the glucocerebrosidase inhibitor CBE exhibited alterations in the ΔΨm and mitochondrial morphology, as well as reduced capacity to form autophagosomes. Pharmacological inhibition of c-Abl or RIPK3 restored mitochondrial function and promoted autophagosome formation, along with an increase in autophagic engulfment of mitochondria in both GD models. In conclusion, the c-Abl-RIPK3 signaling pathway contributes to mitochondrial dysfunction and blockade of autophagy components in the mitochondria, both of which are altered in the neuronopathic forms of GD.